Erratum to Brain PET in Suspected Dementia: Patterns of Altered FDG Metabolism (RadioGraphics, (2014), 34, 3, (684-701), 10.1148/rg.343135065);Brain PET in suspected dementia: Patterns of altered FDG metabolism

Radiographics

Volumn 34, Issue 3, 2014, Pages 684-701

  Brown, Richard K J ^a   Bohnen, Nicolaas I ^a,b   Wong, Ka Kit ^a,b   Minoshima, Satoshi ^c   Frey, Kirk A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTIFACT; BRAIN; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; IMAGE PROCESSING; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION;

ARTIFACTS; BRAIN; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 84900457221     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.343135065     Document Type: Erratum

References (76)

1. Gallucci M, Limbucci N, Catalucci A, Caulo M. Neurodegenerative diseases. Radiol Clin North Am 2008;46(4):799-817, vii.
2. Coleman RE. Positron emission tomography diagnosis of Alzheimer's disease. Neuroimaging Clin N Am 2005;15(4):837-846, x.
3. Silverman DH, Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol Clin North Am 2005;43(1):67-77, x.
4. Van Heertum RL, Tikofsky RS. Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med 2003;33(1):77-85.
5. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007;80(Spec No 2):S160-S167.
6. Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med 2002;16(8):515-525.
7. Matsunari I, Samuraki M, Chen WP, et al. Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J Nucl Med 2007;48(12):1961-1970.
8. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996;47(2):454-461.
9. Perneczky R, Diehl-Schmid J, Drzezga A, Kurz A. Brain reserve capacity in frontotemporal dementia: a voxel-based 18F-FDG PET study. Eur J Nucl Med Mol Imaging 2007;34(7):1082-1087.
10. Perneczky R, Haussermann P, Diehl-Schmid J, et al. Metabolic correlates of brain reserve in dementia with Lewy bodies: an FDG PET study. Dement Geriatr Cogn Disord 2007;23(6):416-422.
11. Perneczky R, Häussermann P, Drzezga A, et al. Fluoro-deoxy-glucose positron emission tomography correlates of impaired activities of daily living in dementia with Lewy bodies: implications for cognitive reserve. Am J Geriatr Psychiatry 2009;17 (3):188-195.
12. Dolan RJ, Bench CJ, Brown RG, Scott LC, Friston KJ, Frackowiak RS. Regional cerebral blood flow abnormalities in depressed patients with cognitive impairment. J Neurol Neurosurg Psychiatry 1992; 55(9):768-773.
13. Rasgon NL, Kenna HA, Geist C, Small G, Silverman D. Cerebral metabolic patterns in untreated postmenopausal women with major depressive disorder. Psychiatry Res 2008;164(1):77-80.
14. Kawasaki K, Ishii K, Saito Y, Oda K, Kimura Y, Ishiwata K. Influence of mild hyperglycemia on cerebral FDG distribution patterns calculated by statistical parametric mapping. Ann Nucl Med 2008;22(3):191-200.
15. Hosaka K, Ishii K, Sakamoto S, et al. Validation of anatomical standardization of FDG PET images of normal brain: comparison of SPM and NEUROSTAT. Eur J Nucl Med Mol Imaging 2005;32 (1):92-97.
16. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42(1):85-94.
17. Buchert R, Wilke F, Chakrabarti B, et al. Adjusted scaling of FDG positron emission tomography images for statistical evaluation in patients with suspected Alzheimer's disease. J Neuroimaging 2005; 15(4):348-355.
18. Yakushev I, Landvogt C, Buchholz HG, et al. Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res 2008;164 (2):143-153.
19. Choo IH, Lee DY, Youn JC, et al. Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study. Alzheimer Dis Assoc Disord 2007;21(2):77-84.
20. Del Sole A, Clerici F, Chiti A, et al. Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study. Eur J Nucl Med Mol Imaging 2008;35 (7):1357-1366.
21. Hirono N, Hashimoto M, Ishii K, Kazui H, Mori E. One-year change in cerebral glucose metabolism in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2004;16(4):488-492.
22. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007; 69(9):871-877.
23. Langbaum JB, Chen K, Lee W, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009;45(4):1107-1116.
24. McMurtray AM, Licht E, Yeo T, Krisztal E, Saul RE, Mendez MF. Positron emission tomography facilitates diagnosis of early-onset Alzheimer's disease. Eur Neurol 2008;59(1-2):31-37.
25. Ishii K, Kono AK, Sasaki H, et al. Fully automatic diagnostic system for early-and late-onset mild Alzheimer's disease using FDG PET and 3D-SSP. Eur J Nucl Med Mol Imaging 2006;33(5):575-583.
26. Patterson JC, Lilien DL, Takalkar A, Kelley RE, Minagar A. Potential value of quantitative analysis
27. Gilman S, Koeppe RA, Little R, et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005;191(suppl 1):S95-S103.
28. Imamura T, Ishii K, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett 1997;235(1-2):49-52.
29. Kono AK, Ishii K, Sofue K, Miyamoto N, Sakamoto S, Mori E. Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP. Eur J Nucl Med Mol Imaging 2007;34(9):1490-1497.
30. Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, Kuhl DE. Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. J Geriatr Psychiatry Neurol 2002; 15(4):200-209.
31. Okamura N, Arai H, Higuchi M, et al. [18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2001;25(2):447-456.
32. Colloby S, O'Brien J. Functional imaging in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17(3):158-163.
33. Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000;162(2):247-256.
34. Ishii K, Hosaka K, Mori T, Mori E. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med 2004; 18(5):447-451.
35. Cordery RJ, Tyrrell PJ, Lantos PL, Rossor MN. Dementia with Lewy bodies studied with positron emission tomography. Arch Neurol 2001;58(3): 505-508.
36. Imamura T, Ishii K, Hirono N, et al. Occipital glucose metabolism in dementia with lewy bodies with and without Parkinsonism: a study using positron emission tomography. Dement Geriatr Cogn Disord 2001;12(3):194-197.
37. Perneczky R, Drzezga A, Boecker H, Förstl H, Kurz A, Häussermann P. Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. Dement Geriatr Cogn Disord 2008;25(6):531-538.
38. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007;14(12): 1357-1362.
39. Foster NL. Validating FDG-PET as a biomarker for frontotemporal dementia. Exp Neurol 2003; 184(suppl 1):S2-S8.
40. Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimers Dement 2008;4(1 suppl 1):S29-S36.
41. Diehl J, Grimmer T, Drzezga A, Riemenschneider M, Förstl H, Kurz A. Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia: a PET study. Neurobiol Aging 2004;25(8):1051-1056.
42. Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET study. Neurobiol Aging 2007;28(1):42-50.
43. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007;130(pt 10):2616-2635.
44. Grimmer T, Diehl J, Drzezga A, Förstl H, Kurz A. Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: a prospective 18F-FDG-PET study. Dement Geriatr Cogn Disord 2004;18(1):32-36.
45. Ibach B, Poljansky S, Marienhagen J, Sommer M, Männer P, Hajak G. Contrasting metabolic impairment in frontotemporal degeneration and early onset Alzheimer's disease. Neuroimage 2004;23(2): 739-743.
46. Jeong Y, Cho SS, Park JM, et al. 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med 2005;46(2):233-239.
47. Kanda T, Ishii K, Uemura T, et al. Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 2008;35(12):2227-2234.
48. Black S, Gao F, Bilbao J. Understanding white matter disease: imaging-pathological correlations in vascular cognitive impairment. Stroke 2009;40(3 suppl):S48-S52.
49. Doyle CA, Slater P. Application of [3H]L-N(G)-nitro-arginine labelling to measure cerebellar nitric oxide synthase in patients with schizophrenia. Neurosci Lett 1995;202(1-2):49-52.
50. Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC. 18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab 2006;26(9):1213-1221.
51. Kuczynski B, Reed B, Mungas D, Weiner M, Chui HC, Jagust W. Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease. Arch Neurol 2008;65 (5):650-655.
52. Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. J Neural Transm Suppl 1998;53:237-250.
53. De Reuck J, Leys D, De Keyser J. Is positron emission tomography useful in stroke? Acta Neurol Belg 1997;97(3):168-171.
54. Duara R, Barker W, Loewenstein D, Pascal S, Bowen B. Sensitivity and specificity of positron emission tomography and magnetic resonance imaging studies in Alzheimer's disease and multi-infarct dementia. Eur Neurol 1989;29(suppl 3):9-15.
55. Meguro K, Doi C, Ueda M, et al. Decreased cerebral glucose metabolism associated with mental deterioration in multi-infarct dementia. Neuroradiology 1991;33(4):305-309.
56. Sultzer DL, Mahler ME, Cummings JL, Van Gorp WG, Hinkin CH, Brown C. Cortical abnormalities associated with subcortical lesions in vascular dementia: clinical and position emission tomographic findings. Arch Neurol 1995;52(8):773-780.
57. Tanaka M, Okamoto K, Hirai S. Cerebral blood flow and oxygen metabolism in vascular dementia evaluated by positron emission tomography: importance
58. Tullberg M, Fletcher E, DeCarli C, et al. White matter lesions impair frontal lobe function regardless of their location. Neurology 2004;63(2):246-253.
59. Kotagal V, Lorincz MT, Bohnen NI. A frontotemporal dementia-like syndrome mimicking postpartum depression detected by 18F fluorodeoxyglucose positron emission tomography. Clin Nucl Med 2012;37(9):e223-e224.
60. Arlt S, Brassen S, Jahn H, et al. Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009;36(7): 1090-1100.
61. Vukovich R, Perneczky R, Drzezga A, Förstl H, Kurz A, Riemenschneider M. Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease. Dement Geriatr Cogn Disord 2009;27(5):474-480.
62. Morbelli S, Piccardo A, Villavecchia G, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging 2010;37(1):36-45.
63. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008;49(3):390-398.
64. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 2009;30(2):404-410.
65. Chételat G, Desgranges B, Landeau B, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008;131(pt 1):60-71.
66. Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE. Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease: pathophysiological implications. Ann N Y Acad Sci 1999;893:350-352.
67. Baron JC, Lebrun-Grandie P, Collard P, Crouzel C, Mestelan G, Bousser MG. Noninvasive measurement of blood flow, oxygen consumption, and glucose utilization in the same brain regions in man by positron emission tomography: concise communication. J Nucl Med 1982;23(5):391-399.
68. Herholz K. Perfusion SPECT and FDG-PET. Int Psychogeriatr 2011;23(suppl 2):S25-S31.
69. Markiewicz PJ, Matthews JC, Declerck J, Herholz K. Robustness of multivariate image analysis assessed by resampling techniques and applied to FDG-PET scans of patients with Alzheimer's disease. Neuroimage 2009;46(2):472-485.
70. Markiewicz PJ, Matthews JC, Declerck J, Herholz K; Alzheimer's Disease Neuroimaging Initiative (ADNI). Verification of predicted robustness and accuracy of multivariate analysis. Neuroimage 2011; 56(3):1382-1385.
71. Zahn R, Garrard P, Talazko J, et al. Patterns of regional brain hypometabolism associated with knowledge of semantic features and categories in Alzheimer's disease. J Cogn Neurosci 2006;18(12): 2138-2151.
72. Foster NL, VanDerSpek AF, Aldrich MS, et al. The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography. J Cereb Blood Flow Metab 1987;7(4):415-420.
73. Wang BW, Lu E, Mackenzie IR, et al. Multiple pathologies are common in Alzheimer patients in clinical trials. Can J Neurol Sci 2012;39(5):592-599.
74. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007;130 (pt 10):2636-2645.
75. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263-269.
76. Burke JF, Albin RL, Koeppe RA, et al. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 2011; 134(pt 6):1647-1657.